A 6-Week, Randomised, Open-Label, Parallel Group, Multi-Centre Study to Compare the Efficacy of Rosuvastatin 10mg With Atorvastatin 10mg in the Treatment of Non-Diabetic Metabolic Syndrome Subjects With Raised LDL-C [low density lipoprotein cholesterol]
Latest Information Update: 03 Nov 2021
Price :
$35 *
At a glance
- Drugs Atorvastatin (Primary) ; Rosuvastatin (Primary)
- Indications Hypercholesterolaemia; Metabolic syndrome
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 14 Dec 2007 Status changed from in progress to completed.
- 30 Sep 2006 New trial record.